社区获得性肺炎抗菌药物治疗的临床观察  

Clinical efficacy of drug therapy for community-acquired pneumonia

作　　者：张继翱 李家瑞[1] 张宇[1] 

机构地区：[1]天津医院急诊科,天津300210

出　　处：《中华医院感染学杂志》2014年第2期347-348,共2页Chinese Journal of Nosocomiology

基　　金：天津市医药卫生重点学科攻关基金项目(10KG118)

摘　　要：目的对比观察莫西沙星、左氧氟沙星和头孢哌酮/舒巴坦在社区获得性肺炎抗感染治疗中的临床疗效及安全性,以降低感染率。方法将180例社区获得性肺炎患者随机分成A、B、C 3组,每组各60例,分别给予莫西沙星、左氧氟沙星、头孢哌酮/舒巴坦静脉滴注治疗,比较3组的临床疗效及安全性。结果 3组的总有效率分别为95.00%、80.00%和78.33%,3组比较差异有统计学意义(P<0.05),莫西沙星组的总有效率高于左氧氟沙星组(χ2=6.17,P<0.05)及头孢哌酮/舒巴坦组(χ2=7.21,P<0.05);3组的细菌清除率分别为93.33%、74.42%和70.45%,3组比较差异有统计学意义(P<0.05),莫西沙星组的细菌清除率均高于其余两组,差异均有统计学意义(P<0.05),不良反应发生率分别为5.00%、8.33%和6.67%,3组比较差异无统计学意义。结论莫西沙星治疗社区获得性肺炎安全、有效,值得临床推广应用。OBJECTIVE To compare and observe the clinical efficacy and safety of moxifloxacin, levofloxacin, cef- perazone-sulbactam in the treatment of comnmnity-acquired pneumonia（CAP） so as to reduce the infection rate. METHODS A total of 180 CAP patients were randomly divided into the group A, B, and C, with 60 cases in each; then the group A was given the intravenous administration of moxifloxacin, the group B treated with the intrave- nous administration of levofloxacin, the group C treated with the intravenous administration of cefoperazone-sul- bactam; the clinical efficacy and safety were observed and compared between the three groups. RESULTS The total effective rate was 95.00% in the group A, 80.00% in the group B, 78.33% in the group C, the difference be- tween the three groups was statistically significant（P〈0.05）; the total effective rate of the moxifloxacin group was higher than that of the levofloxacin group （χ2= 6.17,P〈0.05） and the cefoperazone-sulbactam group （χ2 = 7.21,P〈0.05）. The bacterial clearance rate was 93.33% in the group A, 74.42% in the group B, 70.45% in the group C, the difference between the three groups was statistically significant（P〈0.05）; the bacterial clearance rate of the moxifloxacin group was higher than that of other two groups, the difference was statistically significant （P〈0.05）. The incidence of adverse reactions was 5.00% in the group A, 8.33% in the group B, 6.67% in the group C, the difference between the three groups was not statistically significant. CONCLUSION Moxifloxacin is ef- fective and safe for the treatment of CAP, which is worthy of clinical promotion.

关 键 词：莫西沙星 左氧氟沙星 社区获得性肺炎 

分 类 号：R978.1[医药卫生—药品]